The fluoroquinolones are one of the most useful types of synthetic antibacterial agents due to their broad spectrum of activity against gram-positive and gram-negative bacteria and mycoplasma pneumoniae. Moxifloxacin with fewer side effects and extended half life, is a novel fourth-generation fluoroquinolone antibiotic developed by Bayer AG. Moxifloxacin is prescribed for the treatment of bacterial infections, including respiratory, soft tissue, urinary tract, and joint infections. The authors have synthesized the fluoroquinoline core and the side chain amine. In this paper, the authors report the synthesis of moxifloxacin using difluoroboron complex method.